Company: MLSS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022276
Chunk: 86

Company: MILESTONE SCIENTIFIC INC.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 86
---
, compared to $47,000 in the same period of 2024, a decrease of approximately $6,000, or 13%. The
decline was primarily related to the timing of equipment sales and ongoing efforts to expand awareness and adoption of the Company’s
CompuFlo® Epidural and CathCheck® Systems within the U.S. pain management market.

 22 

Gross
Profit for 2025 and 2024 were as follows: 

    2025  
    2024  
    Change 
  
    Dental 
    $1,600,512  
    $1,794,041  
    $(195,529)
  
    Medical 
     40,358  
     42,179  
     (1,821)
  
    Total gross profit 
    $1,640,870  
    $1,836,220  
    $(195,350)

Consolidated gross profit for the three months ended September 30, 2025,
was approximately $1.6 million, compared to $1.8 million for the same period in 2024, representing a decrease of approximately $195,000,
or 11%. The decline in gross profit was primarily attributable to lower revenue levels during the quarter, particularly within international
and e-commerce dental sales, as well as a slight shift in the sales mix toward lower-margin products and markets. Gross margin remained
strong overall, reflecting the Company’s continued focus on cost management and operational efficiency. 

Selling,
general and administrative expenses for 2025 and 2024 were as follows: 

    2025  
    2024  
    Change 
  
    Dental 
    $891,719  
    $883,666  
    $8,053 
  
    Medical 
     316,544  
     375,189  
     (58,645)
  
    Corporate 
     1,530,748  
     1,805,914  
     (275,166)
  
    Total selling, general and administrative expenses 
    $2,739,011  
    $3,064,769  
    $(325,758)

Consolidated selling, general, and administrative (SG&A) expenses for
the three months ended September 30, 2025, were approximately $2.7 million, compared to $3.1 million for the same